Article
Ethacrynic Acid Enhances the Antitumor Effects of Afatinib in EGFR/T790M-Mutated NSCLC by Inhibiting WNT/Beta-Catenin Pathway Activation.
Disease markers - 1 Jan 2021
Zhang Xuehui, Huang Chaoyuan, Cui Biyu, Pang Yebin, Liang Rong, Luo Xiaoling
Abstract excerpt
Background. Despite afatinib as a new first-line treatment for EGFR L858R and exon 19 deletion or other rare EGFR-mutation patients, the acquired resistance or toxic effects associated with it limited its use clinically. The controlling of acquired resistance or optimization of the afatinib dosage in EGFR/T790M mutation-positive non-small-cell lung cancer (NSCLC) is still an important fundamental problem....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.